Express News | Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BreakingsJul 4 04:00

Top 3 Health Care Stocks That May Crash This Quarter

As of July 3, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.The RSI is a momentum indicator

BenzingaJul 3 21:41

Longboard Pharmaceuticals Price Target Raised to $80.00/Share From $57.00 by Evercore ISI Group

Longboard Pharmaceuticals Price Target Raised to $80.00/Share From $57.00 by Evercore ISI Group

Dow JonesJul 2 23:55

Evercore ISI Group Maintains Outperform on Longboard Pharmaceuticals, Raises Price Target to $80

Evercore ISI Group analyst Josh Schimmer maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Outperform and raises the price target from $57 to $80.

BenzingaJul 2 23:45

Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag

Longboard Pharmaceuticals (LBPH Quick QuoteLBPH - Free Report) gained 14.4% on Jul 1 after it announced that the FDA has granted Breakthrough Therapy designation for its investigational drug, bexicaserin, to treat seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients aged two years or older.

Zacks Jul 2 21:40

Citi Maintains Longboard Pharmaceuticals(LBPH.US) With Buy Rating, Raises Target Price to $45

Citi analyst David Hoang maintains $Longboard Pharmaceuticals(LBPH.US)$ with a buy rating, and adjusts the target price from $40 to $45.According to TipRanks data, the analyst has a success rate of 59

Futu NewsJul 2 19:34 · Ratings